Fuda Cancer Hospital
Fuda Cancer Hospital
China, Guangzhou
The cost of a tumor marker blood test in China typically ranges from $100 to $200. Prices depend on the number of markers tested and the medical facility tier. Patients save around 50% compared to the US, where similar tests cost $200 on average.
Bookimed Expert Insight: Seeking tests at top-tier centers like Yanda International Hospital provides access to modern technology. This JCI accredited facility serves millions of patients and offers high-level Class A care. Specialized centers in Guangzhou, such as Fuda Cancer Hospital, use minimally invasive methods for treatment. These hospitals often provide on-site nuclear medicine experts for more accurate results. International patients benefit from high-volume centers that treat thousands of cases from over 100 countries. Choosing a hospital with JCI accreditation helps maintain international standards for safety and diagnostics.
| China | Turkey | Austria | |
| Tumor Marker Blood Test | from $100 | from $100 | from $100 |
No hidden fees – just official clinic prices. Pay at the clinic for Tumor Marker Blood Test upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Tumor Marker Blood Test and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Tumor Marker Blood Test journey.
Dr. Li Ping, M.D., Ph.D., is Chief Physician and Professor in the Department of Hematology at Shanghai Tongji Hospital, Tongji University School of Medicine. She supervises doctoral and master's students and is an expert in hematologic malignancies.
She earned a Doctor of Medical Science from Nagoya University and completed postdoctoral research. She specializes in diagnosing and treating blood cancers. Her focus includes lymphoid malignancies—leukemias, lymphomas, and multiple myeloma. She treats patients with chemotherapy, hematopoietic stem cell transplantation, targeted therapy, and immunotherapy.
She is a pioneer in China in full-cycle CAR-T therapy for relapsed or refractory blood cancers. She leads and participates in national and international clinical trials. She serves on committees of professional societies, including the China Anti-Cancer Association. She also publishes and trains hematologists.
Dr. Zhang Rong Chun is a leading authority in digestive endoscopy. He serves as the Director of Gastroenterology at Xiamen Humanity Hospital.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.